Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) is projected to issue its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to post earnings of ($0.0539) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:00 PM ET.
Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). On average, analysts expect Oncolytics Biotech to post ($0.29) EPS for the current fiscal year and ($0.22) EPS for the next fiscal year.
Oncolytics Biotech Stock Performance
Shares of ONCY stock opened at $0.41 on Tuesday. The company has a market capitalization of $53.46 million, a P/E ratio of -1.20 and a beta of 1.26. Oncolytics Biotech has a fifty-two week low of $0.38 and a fifty-two week high of $1.30. The stock has a 50 day moving average price of $0.62 and a two-hundred day moving average price of $0.85.
Analysts Set New Price Targets
Get Our Latest Stock Report on Oncolytics Biotech
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc is a clinical-stage biotechnology company developing immunotherapies for cancer. The company’s lead product candidate is pelareorep, an investigational, intravenously delivered reovirus designed to selectively infect and destroy certain tumor cells while stimulating an immune response against cancer.
Oncolytics is evaluating pelareorep in combination with other cancer treatments, including chemotherapy, hormonal therapies and immune checkpoint inhibitors. Its research has focused primarily on breast cancer and gastrointestinal cancers, including pancreatic cancer, with development programs intended to assess the therapy’s potential across multiple tumor types.
Founded in 1998, Oncolytics Biotech is headquartered in Calgary, Alberta, and conducts clinical and corporate activities in North America and other regions through its research and development programs.
Read More
- Five stocks we like better than Oncolytics Biotech
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
